Results 11 to 20 of about 17,593 (256)

Similarities and Distinctions in Actions of Surface-Directed and Classic Androgen Receptor Antagonists. [PDF]

PLoS ONE, 2015
The androgen receptor (AR) surface-directed antagonist MJC13 inhibits AR function and proliferation of prostate cancer (PC) cells. These effects are related to arrest of an AR/chaperone complex in the cytoplasm.
Ji Ho Suh, Arundhati Chattopadhyay, Douglas H Sieglaff, Cheryl Storer Samaniego, Marc B Cox, Paul Webb   +5 more
doaj   +2 more sources

Simulating androgen receptor selection in designer yeast

Synthetic and Systems Biotechnology, 2022
Androgen receptor (AR) mutation is closely associated with prostate cancer (PCa) and is one of the mechanisms of resistance to PCa therapies such as AR antagonists. Although sequencing technologies like next-generation sequencing (NGS) contributes to the
Haoran Zhang, Lu Zhang, Yipeng Xu, Shaoyong Chen, Zhenyi Ma, Mingdong Yao, Fangyin Li, Bo Li, Yingjin Yuan   +8 more
doaj   +1 more source

The epigenetic function of androgen receptor in prostate cancer progression

Frontiers in Cell and Developmental Biology, 2023
Androgen and androgen deprivation (castration) therapies, including androgen receptor antagonists, are clinically used to treat patients with prostate cancer.
Takahiro Sawada, Takahiro Sawada, Yoshiaki Kanemoto, Yoshiaki Kanemoto, Tomohiro Kurokawa, Tomohiro Kurokawa, Tomohiro Kurokawa, Shigeaki Kato, Shigeaki Kato, Shigeaki Kato   +9 more
doaj   +1 more source

In silico prediction of nuclear receptor binding to polychlorinated dibenzofurans and its implication on endocrine disruption in humans and wildlife

Current Research in Toxicology, 2021
Polychlorinated dibenzofurans (PCDFs) are known to cause endocrine disruption in humans and wildlife but the mechanisms underlying this disruption have not been adequately investigated.
Lukman K. Akinola, Adamu Uzairu, Gideon A. Shallangwa, Stephen E. Abechi   +3 more
doaj   +1 more source

Therapeutic potential of TRPM8 antagonists in prostate cancer

Scientific Reports, 2021
Transient receptor potential melastatin-8 (TRPM8) represents an emerging target in prostate cancer, although its mechanism of action remains unclear.
Marzia Di Donato, Carmine Ostacolo, Pia Giovannelli, Veronica Di Sarno, Isabel M. Gomez Monterrey, Pietro Campiglia, Antimo Migliaccio, Alessia Bertamino, Gabriella Castoria   +8 more
doaj   +1 more source

Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: a propensity score-based analysis

Infectious Agents and Cancer, 2021
Background Previous studies hypothesized that androgen deprivation therapy (ADT) may reduce severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infectivity.
Mateus Bringel Oliveira Duarte, Frederico Leal, Juliana Luz Passos Argenton, José Barreto Campello Carvalheira   +3 more
doaj   +1 more source

Spermine is a natural suppressor of AR signaling in castration-resistant prostate cancer

Cell Reports, 2023
Summary: In castration-resistant prostate cancer (CRPC), clinical response to androgen receptor (AR) antagonists is limited mainly due to AR-variants expression and restored AR signaling.
Xiao Li, Fei Li, Fei Ye, Haotian Guo, Wentao Chen, Jia Jin, Yiran Wang, Pengfei Dai, Huili Shi, Hongru Tao, Wenzhen Dang, Yiluan Ding, Mingchen Wang, Hualiang Jiang, Kaixian Chen, Naixia Zhang, Dong Gao, Yuanyuan Zhang, Cheng Luo   +18 more
doaj   +1 more source

Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19

iScience, 2021
Summary: Epidemiological data showing increased severity and mortality of COVID-19 in men suggests a potential role for androgen in SARS-CoV-2 infection.
Qu Deng, Reyaz ur Rasool, Ronnie M. Russell, Ramakrishnan Natesan, Irfan A. Asangani   +4 more
doaj   +1 more source

Expanding armamentarium in advanced prostate cancer management: are all novel antiandrogens the same?

Prostate International, 2021
Prostate cancer (PCa) is the most common cancer in men. Androgen receptor axis plays a crucial role in the carcinogenesis of PCa. The mainstay treatment of prostate cancer is blockage of androgen receptor axis but in a vast majority of patient resistance
Emre Yekedüz, Güngör Utkan, Ravindran Kanesvaran, Yüksel Ürün   +3 more
doaj   +1 more source

Androgen receptor antagonists for prostate cancer therapy [PDF]

Endocrine-Related Cancer, 2014
Androgen deprivation is the mainstay therapy for metastatic prostate cancer (PCa). Another way of suppressing androgen receptor (AR) signaling is via AR antagonists or antiandrogens. Despite being frequently prescribed in clinical practice, there is conflicting evidence concerning the role of AR antagonists in the management of PCa.
Christine, Helsen, Thomas, Van den Broeck, Arnout, Voet, Stefan, Prekovic, Hendrik, Van Poppel, Steven, Joniau, Frank, Claessens   +6 more
openaire   +2 more sources